The initial agreement with Fresenius was entered into in October 2021, with a one-year extension exercised in October 2023. This renewal extends the partnership for an additional two years, until April 1, 2026.

Under the agreement, Biim will continue to supply Fresenius with their wireless pocketable ultrasound devices for use in their dialysis clinics across the United States. As of today, Biim has successfully delivered 285 units in select Fresenius test clinics, positioning the Company for potential expansion to all approx. 3,000 US clinics.

This renewal strengthens Biim's position within the dialysis market and demonstrates continued confidence from a leading global healthcare provider like Fresenius.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.